Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
Date:3/20/2009

CALGARY, March 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim clinical results from its Phase I/II U.K. trial of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting is being held in Banff, Alberta from March 18th to 22nd, 2009. The principal investigator for the trial is Dr. Kevin Harrington of The Institute of Cancer Research.

To date, fifteen head and neck cancer patients have been treated in the Phase I/II trial (REO 011). All but one patient had prior platinum treatment. Of 12 patients evaluable for clinical response, five have experienced Partial Response (PR) and four have experienced Stable Disease (SD) ranging from two to six months. For patients who have been followed for at least six months since their initial treatment, the median progression-free survival (PFS) is currently six months, while the overall survival is currently seven months. The literature suggests that platinum refractory patients typically have a PFS of approximately two months and a median survival ranging from 4.5 to 6.5 months. The overall survival figure may evolve as many of the patients are still alive.

"In patients previously treated with platinum agents, where the response rate (PR and Complete Response (CR)) is generally in the 3-10% range, a response rate of 42% and a 75% clinical benefit rate (SD, PR, and CR) are dramatic," said Dr. Karl Mettinger, Chief Medical Officer for Oncolytics.

The Phase I/II trial has two components. The first is a Phase I, open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously in combination with paclitaxel and carboplatin every three weeks. In this portion of the trial, standard dosages of paclitaxel and car
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to ... the Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment ... meals come from and how agriculture impacts their daily lives. This unique exhibit also ...
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... 30, 2015   GenoSpace , a leading ... and analysis of genomic and other biomedical data, ... joined the company as Vice President of Sales ... "GenoSpace partners with its ... analyze and explore complex sets of genomic, phenotypic ...
(Date:7/30/2015)... and Dallas, TX, USA (PRWEB) , ... July ... ... innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. ... at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... MOUNTAIN VIEW, Calif., May 12 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... quarter ended March 31, 2008 and provided an update ... loss for the 2008,first fiscal quarter, as reported in ... (GAAP), was $14.6 million, compared,to a net loss of ...
... IDIX ) announced today that Idenix management,will present ... Annual Global,Healthcare Conference on Tuesday, May 20, 2008 at ... Monte Carlo, Monaco., The live and archived webcast ... Events" in the Idenix Investor Center at, http://www.idenix.com . ...
... N.J., May 12 Synvista Therapeutics,Inc. (Amex: SYI ) ... Officer of Synvista will present at the upcoming Rodman,& Renshaw ... 12:10 p.m. CEST (6:10 a.m. EDT). The event will be ... Hotel in Monte Carlo., Dr. Berkowitz will discuss the ...
Cached Biology Technology:Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 2Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 3Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 4Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 5Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 6Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 7Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 8Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 9Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates 10Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference 2Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference 3
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 /PRNewswire/ ... and services for gene function analysis and biomarker ... Guide RNA (sgRNA) Knockout Library targeting all human ... specifically and permanently "knock out" a gene,s function. ... provides a high throughput screening tool so that ...
(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... 2009 A canine chromosome 7 locus that confers ... identified through a collaboration between the Behavior Service at ... Medical Genetics at the University of Massachusetts Medical School ... Technology. The findings are published in the January 2010 ...
... lll. Researchers report that Helicobacter pylori , ... environment of the human stomach, directly activates an enzyme ... types of cancer, including gastric cancer. Chronic infection ... factor for several forms of gastric cancer, but researchers ...
... scientific conference has provided new evidence for the ... of spectacular marine life, including deadly jellyfish, basking ... ,South West Marine Ecosystems, meeting, held in Plymouth ... the scientific, conservation, fishing and eco-tourism sectors. The ...
Cached Biology News:Canine compulsive disorder gene identified in dogs 2Canine compulsive disorder gene identified in dogs 3Team finds link between stomach-cancer bug and cancer-promoting factor 2Team finds link between stomach-cancer bug and cancer-promoting factor 3Conference highlights impact of unsettled summer weather on UK marine life 2
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Recombinant Mouse Noggin...
... Deacetylase (HDAC) Antibody Sampler Kit Kit ... Catalog #2062, 40 ul Histone Deacetylase 3 ... Deacetylase 4 (HDAC4) Antibody, Catalog #2072, 40 ... #2082, 40 ul Histone Deacetylase 6 (HDAC6) ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
Biology Products: